{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:43:23Z","timestamp":1770338603829,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hpb.2020.03.002","type":"journal-article","created":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T07:07:38Z","timestamp":1585465658000},"page":"1450-1456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Shohei","family":"Komatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Sofue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motofumi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Kuramitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Awazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Gon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yanagimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirochika","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamichi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2020.03.002_bib1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199903113401001","article-title":"Rising incidence of hepatocellular carcinoma in the United States","volume":"340","author":"El-Serag","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hpb.2020.03.002_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-129-8-199810150-00013","article-title":"Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation","volume":"129","author":"Mor","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hpb.2020.03.002_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00000658-200107000-00010","article-title":"Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years","volume":"234","author":"Poon","year":"2001","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2020.03.002_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/bjs.4838","article-title":"Liver resection for hepatocellular carcinoma in patients with cirrhosis","volume":"92","author":"Wu","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.hpb.2020.03.002_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1148\/radiol.14132958","article-title":"Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update","volume":"273","author":"Ahmed","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.hpb.2020.03.002_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jamcollsurg.2008.01.020","article-title":"Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma","volume":"207","author":"Lam","year":"2008","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.hpb.2020.03.002_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hpb.2020.03.002_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpb.2020.03.002_bib9","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hpb.2020.03.002_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc Cell"},{"key":"10.1016\/j.hpb.2020.03.002_bib11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.hpb.2020.03.002_bib12","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jhep.2008.01.022","article-title":"Novel advancements in the management of hepatocellular carcinoma in 2008","volume":"48","author":"Llovet","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.hpb.2020.03.002_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2020.03.002_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.hpb.2020.03.002_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/cam4.1909","article-title":"Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.hpb.2020.03.002_bib16","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.3748\/wjg.v25.i19.2365","article-title":"Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma","volume":"25","author":"Kuorda","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hpb.2020.03.002_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/hepr.13243","article-title":"Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis","volume":"49","author":"Hiraoka","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.hpb.2020.03.002_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070952","article-title":"Impact of baseline ALBI Grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a Multicenter study","volume":"11","author":"Ueshima","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hpb.2020.03.002_bib19","first-page":"8863","article-title":"Value of alpha-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma","volume":"15","author":"Sanchez","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.hpb.2020.03.002_bib20","doi-asserted-by":"crossref","first-page":"19851","DOI":"10.1038\/srep19851","article-title":"The prognostic Value of alpha-fetoprotein response for advanced-stage hepatocellular carcinoma treated with sorafenib Combined with Transarterial Chemoembolization","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.hpb.2020.03.002_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jhep.2012.02.016","article-title":"Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma","volume":"57","author":"Personeni","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.hpb.2020.03.002_bib22","first-page":"1","article-title":"Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma","author":"Hiraoka","year":"2019","journal-title":"Oncology"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X20300812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X20300812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:29:06Z","timestamp":1761265746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X20300812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1365182X20300812"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2020.03.002","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2020.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}